• 1
    Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007;(1):CD001936.
  • 2
    Bousquet J, Lockey RF, Malling HJ. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53:142.
  • 3
    Lindblad EB. Aluminium adjuvants–in retrospect and prospect. Vaccine 2004;22:36583668.
  • 4
    Glenny AT, Pope C, Waddington H, Wallace U. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bateriol 1926;29:3845.
  • 5
    White RG, Coons AH, Connolly JM. Studies on antibody production. III. The alum granuloma. J Exp Med 1955;102:7382.
  • 6
    Mannhalter JW, Neychev HO, Zlabinger GJ, Ahmad R, Eibl MM. Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clin Exp Immunol 1985;61:143151.
  • 7
    Ramanathan VD, Badenoch-Jones P, Turk JL. Complement activation by aluminium and zirconium compounds. Immunology 1979;37:881888.
  • 8
    Sokolovska A, Hem SL, HogenEsch H. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. Vaccine 2007;25:45754585.
  • 9
    Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 2007;178:52715276.
  • 10
    Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008;453:11221126.
  • 11
    Kool M, Soullie T, van NM, Willart MA, Muskens F, Jung S, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008;205:869882.
  • 12
    Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009;21:2329.
  • 13
    Rask C, Lund L, Lund G, Urioste S, Thorup S, Bergmann K, et al. Optimised allergen: adjuvant ratio potentiates immunogenicity of AlOH-formulated Phleum pratense extract. Allergy 2010;65(Issue Supplement s92):175.
  • 14
    Sundin B, Lilja G, Graff Lonnevig V, Hedlin G, Heilborn H, Norrlind K, et al. Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol 1986;77:478487.
  • 15
    Aas K, Backman A, Belin L, Weeke B. Standardization of allergen extracts with appropriate methods. The combined use of skin prick testing and radio-allergosorbent tests. Allergy 1978;33:130137.
  • 16
    Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167173.
  • 17
    Petersen AB, Gudmann P, Milvang-Gronager P, Morkeberg R, Bogestrand S, Linneberg A, et al. Performance evaluation of a specific IgE assay developed for the ADVIA centaur immunoassay system. Clin Biochem 2004;37:882892.
  • 18
    Malling HJ, Weeke B. Position Paper: ‘Immunotherapy’. Allergy 1993;48 (Issue Supplement s14):935.
  • 19
    Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007;119:780789.
  • 20
    Ciprandi G, Fenoglio D, Cirillo I, Tosca MA, La RM, Licari A, et al. Sublingual immunotherapy: an update on immunologic and functional effects. Allergy Asthma Proc 2007;28:4043.
  • 21
    Shamji MH, Ljorring C, Francis JN, Calderon A, Larche M, Kimber I, et al. Functional rather than immunoreactive levels of IgG(4) correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012;67:217226.
  • 22
    Zenner HP, Baumgarten C, Rasp G, Fuchs T, Kunkel G, Hauswald B, et al. Short-term immunotherapy: a prospective, randomized, double- blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. J Allergy Clin Immunol 1997;100:2329.
  • 23
    Dolz I, Martínez-Cócera C, Bartolomé JM, Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996;51:489500.
  • 24
    Francis JN, James LK, Paraskevopoulos G, Wong C, Calderon MA, Durham SR, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008;121:11201125.
  • 25
    Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003;112:915922.
  • 26
    Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004;4:313318.
  • 27
    Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319325.